Source: DHSC 3.1.2024
This NatPSA supersedes NatPSA/2023/008/DHSC.
The supply of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) continue to be limited, with
supply not expected to return to normal until at least the end of 2024.NOTE A The supply issues
have been caused by an increase in demand for these products for licensed and off-label indications.
• Rybelsus® (semaglutide) tablets are now available in sufficient quantities to support initiation of
GLP1 RA treatment in people with type 2 diabetes (T2DM) in whom new initiation of
GLP-1 RA therapy would be clinically appropriate.
• Byetta® (exenatide) 5micrograms/0.02ml and 10micrograms/0.04ml solution for injection 1.2ml
pre-filled pens will be discontinued in March 2024.
• Victoza® (liraglutide) continues to be out of stock and further stock is not expected until
end of 2024.
• Saxenda® (liraglutide) and Wegovy® (semaglutide) remain available on the NHS via specialist weight
management services.
Do not prescribe GLP-1 RAs licensed for T2DM for off-label indications. Existing stock must be
conserved for patients with T2DM to mitigate the risk of impaired access to treatment and increased
risk in diabetes related complications.
Please refer to the public facing page on the SPS website for an overview of stock availability for all
GLP-1 RAs.
Supplies of insulin remain good, however any surge in demand caused by patients requiring an
escalation of treatment in the absence of GLP-1 RA stock may affect supplies.
Click here to read the source.
